An artificial fusion protein of Arthrobacter oxydans dextranase and Klebsiella pneumoniae alpha-amylase was constructed and expressed in Escherichia coli. Most of the expressed protein existed as an insoluble fraction, which was solubilized with urea. The purified fusion enzyme electrophoretically migrated as a single protein band; M = 137 kDa, and exhibited activities of both dextranase (10.8 U mg(-1)) and amylase (7.1 U mg(-1)), which were lower than that of reference dextranase (13.3 U mg(-1)) and alpha-amylase (103 U mg(-1)). The fusion enzyme displayed bifunctional enzyme activity at pH 5-7 at 37 degrees C. These attributes potentially make the fusion enzyme more convenient for use in sugar processing than a two-enzyme system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10529-009-9967-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma: A case report.
Medicine (Baltimore)
January 2025
Department of Respiratory and Critical Care Medicine, Zhongshan City People's Hospital, Zhongshan, Guangdong Province, China.
Rationale: ROS proto-oncogene 1 (ROS1) fusion is a rare but important driver mutation in non-small cell lung cancer, which usually shows significant sensitivity to small molecule tyrosine kinase inhibitors. With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations of ROS1 have been discovered. Non-muscle myosin heavy chain 9 (MYH9) is a rare fusion partner of ROS1 gene as reported.
View Article and Find Full Text PDFDerivation and Characterization of Isogenic Mutant and Control Human Pluripotent Stem Cell Lines.
Cells
January 2025
Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Dominant optic atrophy (DOA) is the most commonly inherited optic neuropathy. The majority of DOA is caused by mutations in the gene, which encodes a dynamin-related GTPase located to the mitochondrion. OPA1 has been shown to regulate mitochondrial dynamics and promote fusion.
View Article and Find Full Text PDFSulforaphane alleviates membranous nephropathy by inhibiting oxidative stress-associated podocyte pyroptosis.
Iran J Basic Med Sci
January 2025
Department of Nephrology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Objectives: To investigate the natural product sulforaphane (SFN) in protection of membranous nephropathy (MN) by inhibiting oxidative stress-associated podocyte pyroptosis.
Materials And Methods: A passive Heymann nephritis (PHN) model was established and treated with SFN. Clinical manifestations were examined by testing 24-hr urine protein, albumin, total cholesterol, triglyceride, high-density and low-density lipoprotein levels.
Identification of an ethylene-responsive and cell wall-secreting β-1,3-glucanase, VvGLU1, in the early cell regrowth of grape winter buds triggered by exogenous dormancy releasers.
BMC Biol
January 2025
College of Life Sciences, South China Agricultural University, Guangzhou, 510642, China.
Background: Grape (Vitis vinifera) crops encounter significant challenges in overcoming bud endodormancy in warm winter areas worldwide. Research on the mechanisms governing bud dormancy release has focused primarily on stress regulation; however, cell wall regulation of bud meristem regrowth mechanism during the dormancy release remains obscure.
Results: In this study, transmission electron microscopy revealed significant changes in the grape bud cell wall following hydrogen cyanamide (HC) treatment, accompanied by an increase in β-1,3-glucanase activity.
Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.
BMC Ophthalmol
January 2025
Department of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Background: To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Case Presentation: An 80-year-old man with diabetes mellitus had neovascular age-related macular degeneration refractory to treatment with aflibercept 2 mg. Despite ten injections of faricimab, the exudation remained, and we switched to brolucizumab, which resulted in a mild IOI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!